Thierry Poynard

Summary

Country: France

Publications

  1. ncbi Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:481-92. 2003
  2. pmc Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
    Thierry Poynard
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:34. 2006
  3. pmc Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
    Vlad Ratziu
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:6. 2006
  4. ncbi A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
  5. ncbi Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 13:895-900. 2008
  6. ncbi Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
    Francoise Imbert-Bismut
    Service of Biochemistry, hôpital La Pitié Salpêtrière, Paris, France
    Clin Chem Lab Med 42:323-33. 2004
  7. ncbi Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy
    Robert P Myers
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    AIDS 18:75-9. 2004
  8. ncbi Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Dominique Thabut
    Services d Hépato gastroentérologie, Group Hospitalier Pitié Salpêtrièe, Paris, France
    Am J Gastroenterol 101:1260-7. 2006
  9. doi FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program
    Thierry Poynard
    APHP UPMC Liver Center, Paris, France
    J Hepatol 54:227-35. 2011
  10. doi Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
    Thierry Poynard
    University Pierre and Marie Curie Liver Center, Paris, France
    Antivir Ther 15:617-31. 2010

Detail Information

Publications111 found, 100 shown here

  1. ncbi Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:481-92. 2003
    ..In conclusion, these biochemical markers of fibrosis and activity could be used as surrogate markers for liver biopsy in patients with chronic hepatitis C, both for the initial evaluation and for follow-up...
  2. pmc Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
    Thierry Poynard
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:34. 2006
    ..The aim was to develop and validate a new biomarker of non alcoholic steato hepatitis (NASH) the NashTest (NT) in patients with NAFLD...
  3. pmc Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
    Vlad Ratziu
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:6. 2006
    ..The aim of this study was to determine the diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral hepatitis and alcoholic liver disease (FibroTest, FT), in patients with NAFLD...
  4. ncbi A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
    ..We compared the 5-year prognostic value of the FibroTest with biopsy staging for predicting cirrhosis decompensation and survival in patients with chronic HCV infection...
  5. ncbi Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 13:895-900. 2008
    ..Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients. ADV combined with pegylated interferon (PEG-IFN) has never been evaluated in this population...
  6. ncbi Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
    Francoise Imbert-Bismut
    Service of Biochemistry, hôpital La Pitié Salpêtrière, Paris, France
    Clin Chem Lab Med 42:323-33. 2004
    ..075+/-0.004 and 0.068+/-0.004, respectively. The low intra-laboratory and intra-patient variability in Fibrotest and Actitest results confirm Fibrotest and Actitest reliability...
  7. ncbi Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy
    Robert P Myers
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    AIDS 18:75-9. 2004
    ..Pegylated interferon alpha (PEG-IFN-alpha) and ribavirin is the most effective available treatment for chronic hepatitis C virus (HCV) infection. Its role in HIV/HCV-co-infected patients who have failed IFN-based therapy is unclear...
  8. ncbi Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Dominique Thabut
    Services d Hépato gastroentérologie, Group Hospitalier Pitié Salpêtrièe, Paris, France
    Am J Gastroenterol 101:1260-7. 2006
    ....
  9. doi FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program
    Thierry Poynard
    APHP UPMC Liver Center, Paris, France
    J Hepatol 54:227-35. 2011
    ....
  10. doi Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
    Thierry Poynard
    University Pierre and Marie Curie Liver Center, Paris, France
    Antivir Ther 15:617-31. 2010
    ..We aimed to review evidence-based published data of biomarkers that have been validated as non-invasive alternatives to biopsy as end points for HBV and HCV infection trials...
  11. pmc Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
    Thierry Poynard
    APHP UPMC Liver Center, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    BMC Gastroenterol 10:40. 2010
    ..One challenge was to use them for estimating the prevalence of fibrosis, identifying independent risk factors and to propose screening strategies in the general population...
  12. ncbi Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population
    Thierry Poynard
    APHP UPMC Paris Liver Center, Paris, France
    J Hepatol 57:541-8. 2012
    ..We aimed at validating this concept by comparing LFP using FT vs. biopsy (P1) and then at applying the non-invasive method to a large population (P2)...
  13. pmc Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
    Thierry Poynard
    APHP UPMC Paris Liver Center, Paris, France
    BMC Gastroenterol 11:39. 2011
    ..The aims were to estimate the prevalence of RFPN and of proven failures, and to identify factors associated with their occurrences...
  14. ncbi Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial
    Laetitia Fartoux
    AP HP, Hopital Saint Antoine, Paris, France
    Clin Gastroenterol Hepatol 5:502-7. 2007
    ..We designed a randomized controlled trial comparing the efficacy of prolonged IFN alfa-2a treatment vs nontreatment on complication-free survival in patients with compensated HCV cirrhosis...
  15. ncbi Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B
    Robert P Myers
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Hepatol 39:222-30. 2003
    ..Liver biopsy is the gold standard for assessing hepatitis B virus (HBV)-related histology. The aim was to determine the diagnostic utility of noninvasive serum markers in patients with chronic hepatitis B...
  16. pmc Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study
    Helmi M'Kada
    Service de Biochimie Métabolique, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    PLoS ONE 7:e42418. 2012
    ..Identification of drug-induced liver disease (DILI) is difficult, even among hospitalized patients. The aim of this pilot study was to assess the impact of a specific strategy for DILI screening...
  17. doi Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes
    Sophie Jacqueminet
    Service de Diabetologie, APHP GHPS, Paris, France
    Clin Gastroenterol Hepatol 6:828-31. 2008
    ..We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) in patients with diabetes...
  18. pmc An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
    PLoS ONE 3:e2573. 2008
    ..We compared the 4-year prognostic value of combining FT-AT and viral load for a better definition of the inactive carrier status...
  19. ncbi Viral hepatitis C
    Thierry Poynard
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Universite, Paris, France
    Lancet 362:2095-100. 2003
    ..These antiviral treatments reduce liver fibrosis progression and can reverse cirrhosis. Unfortunately, even in developed countries, death due to hepatitis C is increasing because of inadequate detection and treatment...
  20. ncbi Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients
    Robert P Myers
    Department of Hepatology and Gastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    AIDS 17:721-5. 2003
    ..Our aim was to determine the operating characteristics of a non-invasive index of biochemical markers for the prediction of fibrosis in patients with HIV/HCV co-infection...
  21. ncbi Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:75-85. 2003
    ..In conclusion, sustained disappearance of the virus is associated with reduction of steatosis in genotype 3 as well as a correction of baseline low serum cholesterol...
  22. doi Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    J Hepatol 56:49-54. 2012
    ..The course of the disease is determined by the rapidity of liver fibrosis progression (LFP). The influence of interferon on LFP in coinfected patients has yet not been evaluated by comparative liver biopsies...
  23. ncbi Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B
    Dominique Thabut
    Hepato Gastroenterology Unit, Hopital Pitie Salpetriere, Paris, France
    Eur J Gastroenterol Hepatol 16:1367-73. 2004
    ..The clinical features, course and viral mutations associated with the emergence of viral resistance in this population have not been well studied...
  24. ncbi Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Clin Chem 50:1344-55. 2004
    ....
  25. ncbi Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study
    Samy Louafi
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Cancer 109:1384-90. 2007
    ..In a Phase II trial involving previously untreated patients with advanced HCC, the more favorable schedule from a previous pilot study was evaluated...
  26. ncbi Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience
    Mona Munteanu
    Biopredictive, and Groupe Hospitalier Pitié Salpêtrière, 47 83 boulevard de l Hopital, Paris, France
    J Gastrointestin Liver Dis 17:187-91. 2008
  27. pmc Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers
    Thierry Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Universite Paris VI, CNRS UMR, Paris, France
    PLoS ONE 3:e3857. 2008
    ..The aim was to identify factors associated with LSM accuracy using FT as a non-invasive endpoint and vice versa...
  28. doi A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
    Raluca Pais
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    J Hepatol 59:550-6. 2013
    ..e., steatosis alone or with mild inflammation not qualifying for steatohepatitis) can evolve towards steatohepatitis (NASH) with fibrosis...
  29. ncbi Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1
    Yves Benhamou
    Groupe Hospitalier Pitie Salpetriere, Service de d Hépato Gastroentérologie, Paris, France
    J Hepatol 44:62-7. 2006
    ..Adefovir dipivoxil (10 mg once-daily) was added to antiretroviral therapy including lamivudine in 35 HIV/HBV co-infected patients...
  30. ncbi Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study
    Thierry Poynard
    Service d Hepato Gastroenterologie, APHP UPMC Paris Liver Center, Paris, France
    J Hepatol 58:452-9. 2013
    ..EPIC(3) included a prospective trial assessing long-term peginterferon alfa-2b (PegIFNα-2b) maintenance therapy in patients with METAVIR fibrosis scores (MFS) of F2 or F3 who previously failed hepatitis C retreatment...
  31. doi Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis
    Thierry Poynard
    Assistance Publique Hopitaux de Paris, Université Pierre et Marie Curie Liver Center, Paris, France
    Clin Gastroenterol Hepatol 10:657-63.e7. 2012
    ..We investigated whether this controversy results from limitations of biopsy analysis for intermediate-stage fibrosis and inappropriate determination of the standard area under the receiver-operator characteristic curve (AUROC)...
  32. doi The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption
    Francoise Imbert-Bismut
    Department of Biochemistry, APHP Groupe Hospitalier Pitié Salpétrière, Paris, France
    Eur J Gastroenterol Hepatol 21:18-27. 2009
    ..The aim was to improve the accuracy of the percentage of CDT by taking into account the presence of fibrosis and steatosis, estimated using biomarkers FibroTest and SteatoTest...
  33. doi Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up
    Ruxandra Călin
    AP HP, Service des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    J Clin Virol 58:408-14. 2013
    ..The dynamic of liver disease in co-infected patients is important to understand for appropriate clinical management. Conflicting data surround the role played by genotype-G HBV (HBV-G) during the course of HIV co-infection...
  34. ncbi Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure
    Vincent Di Martino
    Service d Hepato Gastroenterologie, GH Pitié Salpétrière, Paris, France
    Hepatology 40:1426-33. 2004
    ..Pregnancies may have a beneficial impact on the long-term progression of liver fibrosis...
  35. pmc Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection
    Etienne Patin
    Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Necker Medical School, INSERM Unité 980, Paris, France
    Gastroenterology 143:1244-52.e1-12. 2012
    ..Only a fraction of patients with chronic HCV infection develop liver fibrosis, a process that might also be affected by genetic factors. We performed a 2-stage GWA study of liver fibrosis progression related to HCV infection...
  36. ncbi In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir
    Olivier Lada
    Virology, AP HP Pitié Salpêtrière Hospital, Paris, France
    Antivir Ther 9:353-63. 2004
    ..The excellent activity of TDF on lamivudine-resistant virus independently of the resistance mutation profile offers an interesting treatment alternative to HIV-HBV coinfected patients...
  37. doi Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis
    Benjamin Terrier
    Department of Internal Medicine, Universite Pierre et Marie Curie, Paris, France
    J Hepatol 55:756-61. 2011
    ..Data are lacking in HIV-HCV coinfected patients...
  38. doi Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
    Thierry Poynard
    Service d Hepatologie, Université Pierre et Marie Curie Liver Center, hôpital La Pitié Salpêtrière, Paris, France
    Gastroenterology 136:1618-28.e2. 2009
    ..Alternate options are needed for patients who relapse or do not respond to therapy...
  39. ncbi Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages
    Thierry Poynard
    Assistance Publique Hôpitaux de Paris Groupe Hospitalier Pitié Salpêtrière, Paris, France
    Clin Chem 53:1615-22. 2007
    ..The aim of this study was to assess the relationships between the AUC and the prevalence of each fibrosis stage and to elaborate simple methods of standardization...
  40. ncbi Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study
    Amani Asnacios
    Department of Hepato gastro enterology, Pitie Salpetriere Hospital, Paris, France
    Cancer 112:2733-9. 2008
    ....
  41. ncbi Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection
    Nadia Alatrakchi
    Laboratoire d Immunologie Cellulaire et Tissulaire INSERM U543, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    AIDS 18:121-3. 2004
    ..This suggests that IFN+R therapy might compromise virus-specific immune defenses in immunosuppressed patients...
  42. doi Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis
    Didier Lebrec
    INSERM, Unité 773, Centre de Recherche Biomédicle Bichat Beaujon CRB3, Paris, France and Service d Hépatologie, Hopital Beaujon, Clichy, France
    Gastroenterology 138:1755-62. 2010
    ..We performed a randomized, placebo-controlled, double-blind trial of its effects in patients with cirrhosis...
  43. ncbi Sampling variability of liver biopsy in nonalcoholic fatty liver disease
    Vlad Ratziu
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Gastroenterology 128:1898-906. 2005
    ..The aim of this study was to assess the sampling error of liver biopsy and its impact on the diagnosis and staging of NASH...
  44. ncbi Treatment of cirrhotic patients in the pegylated interferon era
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Dig Liver Dis 36:S344-8. 2004
    ..Non-invasive biochemical markers of liver fibrosis should facilitate the management...
  45. ncbi Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index
    Robert P Myers
    Department of Gastroenterology and Hepatology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Dig Dis Sci 48:146-53. 2003
    ..In conclusion, an index of five biochemical markers accurately predicts significant hepatitis C-related fibrosis and is superior to traditional markers...
  46. pmc Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso
    Philippe Bonnard
    Maladies Infectieuses, Hopital Tenon, UPMC Univ Paris 06, UPMC Paris Liver Center, Paris, France
    Am J Trop Med Hyg 82:454-8. 2010
    ..This study shows that the results of alternative methods concord with those of histology in HBV-infected patients in Burkina Faso. These alternative techniques could help physicians to identify patients requiring treatment...
  47. ncbi Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection
    Thierry Poynard
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Am J Gastroenterol 100:1970-80. 2005
    ..The aim was to use these markers in a prospective study of patients treated with lamivudine in order to assess the impact of treatment, as well as the factors associated with fibrosis progression...
  48. ncbi Fat, diabetes, and liver injury in chronic hepatitis C
    Vlad Ratziu
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Curr Gastroenterol Rep 6:22-9. 2004
    ..Exciting new data are expanding our understanding of the mechanisms of steatogenesis in HCV infection and providing potential links between insulin resistance or hyperglycemic states and liver fibrogenesis...
  49. pmc Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data
    Thierry Poynard
    APHP UPMC Liver Center, Paris, France
    PLoS ONE 7:e30325. 2012
    ..The aim of this study was to perform an overview of 3 studies which assessed the performance of non-invasive markers of fibrosis (FibroTest), steatosis (SteatoTest) and steato-hepatitis (NashTest, ActiTest) in these patients...
  50. ncbi Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy
    Patrick Ingiliz
    Hepatology Department, AP HP, GH Pitié Salpétrière, Paris, France
    Hepatology 49:436-42. 2009
    ..The presence of NASH was correlated with high fasting glycemia and insulin levels, not with liver mitochondrial function or mitochondrial DNA content...
  51. doi Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection
    Bertrand Nalpas
    Unité d Hépatologie, Institut National de la Sante et de la Recherche Medicale, U567, Hopital Cochin, Paris, France
    Gut 59:1120-6. 2010
    ..Only a minority of patients with chronic hepatitis C virus (HCV) infection develops severe liver fibrosis, a process that may be controlled by human genetic factors...
  52. doi Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial
    Vlad Ratziu
    Universite Pierre et Marie Curie Paris VI, Assistance Publique Hopitaux de Paris, Service d Hepatogastroenterologie, Paris, France
    Gastroenterology 135:100-10. 2008
    ..Nonalcoholic steatohepatitis (NASH) is a liver disease that complicates insulin-resistant states. This trial tested the efficacy and safety of rosiglitazone, an insulin-sensitizing agent, in patients with NASH...
  53. doi Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard
    Thierry Poynard
    Hepato Gastroenterology, APHP UPMC Liver Center, Paris, France
    J Hepatol 58:928-35. 2013
    ..The aim was to assess the applicability and performances of SWE for the diagnosis of fibrosis as compared with FibroTest (FT) and liver stiffness measurement (LSM) by transient elastography using two probes (TE-M and TE-XL)...
  54. ncbi Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C
    Robert P Myers
    Department of Hepato Gastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    Am J Gastroenterol 97:2419-25. 2002
    ..The aims of this study were: 1) to compare an index of five biochemical markers with historical features; and 2) to determine the utility of combining these features with the five-marker index for the prediction of significant fibrosis...
  55. doi What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI)
    Helmi M'Kada
    Assistance Publique Hôpitaux de Paris UPMC Liver Center, Paris, France
    Regul Toxicol Pharmacol 60:290-5. 2011
    ..Regulatory agencies still use ULN-ALT for the definition of drug adverse events such as drug induced liver disease (DILI)...
  56. ncbi Treatment of hepatitis C virus: the first decade
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Semin Liver Dis 24:19-24. 2004
    ..Pegylated interferons used alone or in combination with ribavirin provide improved treatment options for different patient groups with chronic hepatitis C...
  57. pmc Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series
    Hélène Prodanovic
    Assistance Publique Hopitaux de Paris, Service de Pneumologie et Reanimation, Groupe Hospitalier Pitie Salpetriere, Paris, France
    BMC Gastroenterol 7:2. 2007
    ..Liver failure has been suspected to be a risk factor for aspergillosis...
  58. ncbi Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure
    Dominique Thabut
    AP HP Service d Hépato Gastroentérologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hepatology 46:1872-82. 2007
    ..001). In multivariate analysis, only model for end-stage liver disease score and presence of SIRS, but not infection, remained associated with a poor outcome...
  59. ncbi Portal lymphocytic infiltrate in alcoholic liver disease
    Magali Colombat
    Service Central d Anatomie Pathologique, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hum Pathol 33:1170-4. 2002
    ..These results suggest that lymphocytes may play a role in the pathogenesis of alcohol-induced liver fibrosis...
  60. ncbi Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection
    Michal Abel
    INSERM, U561 Equipe AVENIR, Paris, France
    Hepatology 44:1607-16. 2006
    ..Therapeutic modulation of the intrahepatic balance between specific and bystander CD8 T cells might be beneficial in patients with chronic hepatitis C...
  61. pmc Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants
    Olivier Lada
    Departments of Virology, Hepato Gastro Enterology, AP HP Pitié Salpêtrière Hospital, Paris, France
    J Virol 80:2968-75. 2006
    ..The consequences of this selection process with regard to vaccine efficacy, diagnosis, and clinical evolution remain partially unknown...
  62. ncbi Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus
    Damien Sene
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, Paris, France
    J Rheumatol 31:2199-206. 2004
    ..To describe epidemiological, clinical, and immunological characteristics and the longterm course of persistent mixed cryoglobulinemia (MC) in patients infected with hepatitis C virus (HCV)...
  63. ncbi The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV
    Heidi Hannon
    Nephrology Department, Hôpital Pitié Salpétrière and CNRS UPRESA 8087, Paris, France
    Nephrol Dial Transplant 19:386-90. 2004
    ..Recently, lower doses of ADV were shown to be effective for the treatment of HIV-1 patients with chronic lamivudine (LAM)-resistant hepatitis B...
  64. ncbi Ethanol-induced inhibition of cytokine release and protein degranulation in human neutrophils
    Julien Taieb
    Service d Immunologie et d Hématologie et INSERM U479, CHU Xavier Bichat, Paris, France
    J Leukoc Biol 72:1142-7. 2002
    ..8%), an action that may delay the repair of alcoholic liver damage. These findings suggest that ethanol may modulate three major cytokines involved in alcoholic liver diseases, IL-8, TNF-alpha, and HGF, via three different mechanisms...
  65. ncbi Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosis
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitié Salpêtrière AP HP, University Paris 6, Paris, France
    Antivir Ther 15:281-91. 2010
    ..Incorporation of appropriately validated non-invasive assessments of liver fibrosis will likely improve the clinical care of patients with HCV infection...
  66. ncbi FAS promoter polymorphisms correlate with activity grade in hepatitis C patients
    Dorian McIlroy
    Laboratoire d Immunologie Cellulaire et Tissulaire bService de Gastroentérologie, Hopital Pitie Salpetriere, Paris, France
    Eur J Gastroenterol Hepatol 17:1081-8. 2005
    ..Hepatocytes are susceptible to FAS-mediated apoptosis. The impact of polymorphisms in the FAS gene on histopathological features of HCV infection was therefore investigated...
  67. ncbi Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests
    Olivier Lucidarme
    Radiology Department, Pitie Salpetriere Hospital, Assistance Publique Hôpitaux de Paris and Université Paris 6 Pierre et Marie Curie, Paris, France
    Eur J Radiol 81:1413-9. 2012
    ..To assess the cost-effectiveness of three colorectal-cancer (CRC) screening strategies in France: fecal-occult-blood tests (FOBT), computed-tomography-colonography (CTC) and optical-colonoscopy (OC)...
  68. ncbi Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred
    Arnaud Galbois
    Universite Pierre et Marie Curie, Service d Hepato Gastroenterologie, Hôpital de la Pitié Salpêtrière AP HP, Paris, France
    J Hepatol 52:839-45. 2010
    ....
  69. pmc Hirsch index and truth survival in clinical research
    Thierry Poynard
    University Pierre et Marie Curie Assistance Publique Hôpitaux de Paris Liver Center, Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    PLoS ONE 5:e12044. 2010
    ..We hypothesized that publications with a first author having a higher Hirsch' index value (h-I), which quantifies and predicts an individual's scientific research output, should have a longer half-life...
  70. ncbi Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities
    Georgia Malamut
    Hepatology and Gastroenterology Department, Hopital Europeen Georges Pompidou, Paris, France
    J Hepatol 48:74-82. 2008
    ..Liver lesions associated with primary hypogammaglobulinemia have been poorly described. We aimed to assess the clinical, histological and immune features and outcome of hepatic injury in patients with primary hypogammaglobulinemia...
  71. ncbi Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules
    Julien Taieb
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Cancer 98:2664-70. 2003
    ..Therefore, the authors evaluated the activity and toxicity of two such combinations in patients with HCC...
  72. ncbi Recombinant activated factor VII in chronic liver diseases: should we be afraid of thromboembolic events?
    Dominique Thabut
    Universite Pierre et Marie Curie, Service d Hepato Gastroenterologie, Hôpital de la Pitié Salpêtrière AP HP, Paris, France
    J Hepatol 55:483-5. 2011
  73. ncbi Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?
    Vlad Ratziu
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, INSERM UMRS_893, CdR Saint Antoine, Paris, France
    Biomark Med 3:353-61. 2009
    ..A noninvasive diagnosis of NASH would facilitate screening and monitoring of populations at risk, as well as the conduct of therapeutic trials...
  74. ncbi Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis
    Julien Taieb
    Hepatology Department, Pitie Salpetriere Hospital, 47, Boulevard de l Hopital, 75651, Cedex 13, Paris, France
    J Hepatol 36:342-8. 2002
    ..As AH is accompanied by inflammation, neutrophilia and polymorphonuclear neutrophil (PMN) infiltration of the liver, we postulated that PMN could be a source of HGF in such patients...
  75. ncbi FibroMAX: towards a new universal biomarker of liver disease?
    Rachel Morra
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Expert Rev Mol Diagn 7:481-90. 2007
    ..The possible causes of false-negative and false-positive results are also better identified. These tests, which are now available in 50 countries, can facilitate the screening and management of the most frequent liver diseases...
  76. ncbi Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
    Thierry Poynard
    Gastroenterology 128:1146-8; author reply 1148. 2005
  77. ncbi Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis
    Damien Sene
    Department of Internal Medicine, La Pitie Salpetriere Hospital, France
    Clin Biochem 39:715-21. 2006
    ..We assessed the reliability of non-invasive biological scoring indexes (Fibrotest-Actitest [FT-AT], Forns, APRI, age-platelet, platelet, hyaluronic acid) as non-invasive alternatives to liver biopsy (LB) in 138 HCV-infected patients...
  78. ncbi Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores
    Georges Ferard
    Faculte de Pharmacie, Universite Louis Pasteur de Strasbourg, Illkirch, France
    Clin Chem Lab Med 44:400-6. 2006
    ..8% and 3.3% for ALT and GGT, respectively. For each enzyme, it also permitted the retention of a common reference interval for a set of calibrated methods and the improvement of inter-laboratory coherency of Fibrotest and Actitest scores...
  79. ncbi Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease
    Sylvie Naveau
    Department of Hepato Gastroenterology, Hopital Antoine Beclere, Clamart, France
    Clin Gastroenterol Hepatol 3:167-74. 2005
    ..The aim of this study was to determine the diagnostic use of noninvasive markers of fibrosis in patients with chronic alcoholic liver disease...
  80. ncbi [Mucosa-associated lyphoid tissue hepatic lymphoma with low-grade malignancy associated with primary biliary cirrhosis]
    Lamia Golli
    Gastroenterol Clin Biol 27:127-9. 2003
  81. ncbi Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group
    John McHutchison
    GI Hepatology Research, Duke Clinical Research Institute, Durham, North Carolina 27707, USA
    Clin Gastroenterol Hepatol 4:1214-1220. 2006
    ..In this article, we summarize those discussions and attempt to highlight many of the hurdles and unanswered questions as we attempt to move forward and develop therapies to combat liver fibrosis...
  82. ncbi Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious
    Vlad Ratziu
    Hepatology 44:802-5. 2006
  83. ncbi The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease
    Dominique Thabut
    Department of Hepato Gastroenterology, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 CNRS UMR 8149, Paris Cedex 13, France
    J Hepatol 44:1175-85. 2006
    ..The aim was to identify a panel of biomarkers (AshTest) for the diagnosis of alcoholic steato-hepatitis (ASH), in patients with chronic alcoholic liver disease...
  84. ncbi FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
    Thierry Poynard
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Expert Rev Mol Diagn 5:15-21. 2005
    ..The possible causes of false negatives and positives are also better identified. These tests, which are now available in 12 countries, can facilitate the screening and management of the most frequent liver diseases...
  85. ncbi FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C
    Rachel Morra
    Hepatology 47:353-4; author reply 354-6. 2008
  86. ncbi [Non invasive markers using for the assessment of fibrosis in hepatitis C]
    Jean Pierre Zarski
    Clinique universitaire d hepato gastroentérologie, pôle DIGI DUNE, Unité INSERM U 548, CHU de Grenoble, Grenoble Cedex 9
    Gastroenterol Clin Biol 31:4S34-9. 2007
    ..Diagnostic accuracy is improved by the using of all the markers, especially of Fibrotest. Transient elastography is also a promising method for assessing the severity of cirrhosis...
  87. ncbi Diagnostic value of FibroTest with normal serum aminotransferases
    Thierry Poynard
    Hepatology 43:374-5; author reply 375-6. 2006
  88. ncbi Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection
    Laurent Alric
    Service de Medecine Interne, Pavillon Dieulafoy, CHU Purpan, Toulouse, France
    Gastroenterology 123:1494-9. 2002
    ....
  89. ncbi Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level
    Valerie Boige
    Gastrointestinal Oncology Unit, Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 42:456-9. 2006
    ..51 and 3 ULN. However, the antitumour activity of single agent CPT-11 was not significant in advanced HCC...
  90. ncbi Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study
    Pierre Pradat
    Department of Hepatology, Hotel Dieu, Lyon, France
    Hepatology 36:973-7. 2002
    ..In this subset of patients, the indication of liver biopsy and the potential benefit of therapy need to be further evaluated. These results suggest the need to revisit the algorithm for liver biopsy practice...
  91. ncbi Truth survival in clinical research: an evidence-based requiem?
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Ann Intern Med 136:888-95. 2002
    ..Factors associated with the survival of truth of clinical conclusions in the medical literature are unknown. The authors hypothesized that conclusions derived from studies using better methodology should have a longer half-life...
  92. ncbi Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
    John G McHutchison
    Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
    Hepatology 35:688-93. 2002
    ..In conclusion, measurement of hepatic HCV RNA before or after therapy reflects changes observed in serum HCV RNA, and correlates inversely with hepatic inflammation and fibrosis, but otherwise has minimal clinical use...
  93. ncbi Noninvasive prediction of fibrosis in patients with chronic hepatitis C
    Dominique Thabut
    Hepatology 37:1220-1; author reply 1221. 2003
  94. ncbi NASH: a hidden and silent fibroser finally revealed?
    Vlad Ratziu
    J Hepatol 42:12-4. 2005
  95. ncbi Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C
    Maria Alessandra Rosenthal-Allieri
    Laboratoire central d immunologie, CHU de Nice, Hopital de l Archet, Nice Université de Nice Sophia Antipolis, 151 route Saint Antoine de Ginistière, Nice
    Gastroenterol Clin Biol 31:815-21. 2007
    ..The aims of this study were to evaluate the analytical variability of the Fibrotest-Actitest proteins alpha 2-macroglobulin, haptoglobin and apolipoprotein-A1, and to assess their impact on the Fibrotest-Actitest scores...
  96. doi Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers
    Mireen Friedrich-Rust
    Department of Internal Medicine, JW Goethe University Clinic, Frankfurt, Germany
    J Thorac Cardiovasc Surg 135:560-7. 2008
    ..Therefore, early detection of fibrosis is essential to identify patients at risk. Transient elastography has been evaluated for noninvasive staging of liver fibrosis in a multitude of studies...
  97. ncbi Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria
    Gilles Bommelaer
    Service d Hepato Gastroenterologie, hôpital de l Hôtel dieu, Clermont Ferrand
    Gastroenterol Clin Biol 28:554-61. 2004
    ....
  98. doi Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations
    Mona Munteanu
    Clin Biochem 41:1113-4. 2008
  99. pmc Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
    ....
  100. ncbi The elusiveness of "normal" ALT in fatty liver
    Vlad Ratziu
    Hepatology 39:1172; author reply 1173. 2004
  101. ncbi The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C
    Sophie Le Calvez
    Hepatology 39:862-3; author reply 863. 2004